Y-mAbs(US:YMAB) Prnewswireยท2025-08-07 22:44Core Viewpoint - Monteverde & Associates PC is investigating the proposed sale of Y-mAbs Therapeutics, Inc. to SERB Pharmaceuticals, where Y-mAbs shareholders are set to receive $8.60 in cash per share, raising questions about the fairness of the deal [1]. Company Overview - Monteverde & Associates PC is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report and has successfully recovered millions for shareholders [1]. - The firm operates from the Empire State Building in New York City and specializes in class action securities litigation [2]. Legal Context - The firm is actively seeking to determine if the proposed transaction for Y-mAbs is equitable for its shareholders [1]. - Shareholders with concerns or seeking additional information can contact the firm directly [3].